Last reviewed · How we verify

AK120 — Competitive Intelligence Brief

AK120 (AK120) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific T cell engager. Area: Oncology.

phase 3 Bispecific T cell engager CD3 and tumor-associated antigen (specific target not publicly disclosed) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AK120 (AK120) — Akesobio Australia Pty Ltd. AK120 is an engineered T cell engager that redirects patient T cells to recognize and eliminate cancer cells expressing specific tumor antigens.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AK120 TARGET AK120 Akesobio Australia Pty Ltd phase 3 Bispecific T cell engager CD3 and tumor-associated antigen (specific target not publicly disclosed)
AK101 SC AK101 SC Akeso phase 3 Bispecific T cell engager (BiTE) CD3 and PSMA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific T cell engager class)

  1. Akesobio Australia Pty Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AK120 — Competitive Intelligence Brief. https://druglandscape.com/ci/ak120. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: